A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate
Launched by BRISTOL-MYERS SQUIBB · Mar 3, 2006
Trial Information
Current as of June 13, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of accelerated phase or blast phase CML or Ph+ ALL
- • Intolerant or resistant to imatinib mesylate
- • 18 years of age or older
- • ECOG performance 0-2 (greater than 50% of time out of bed)
- • Adequate liver and kidney function
- Exclusion Criteria:
- • Pregnant or breastfeeding females
- • History of significant cardiac disease
- • History of significant bleeding disorder (not CML)
- • Prisoners
About Bristol Myers Squibb
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. With a robust portfolio of products across multiple therapeutic areas, including oncology, immunology, cardiovascular, and fibrotic diseases, BMS emphasizes cutting-edge research and a commitment to advancing medical science through clinical trials. The company is driven by a mission to provide transformative therapies, leveraging collaboration and scientific expertise to address unmet medical needs and improve patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Louisville, Kentucky, United States
New York, New York, United States
Indianapolis, Indiana, United States
Cincinnati, Ohio, United States
Atlanta, Georgia, United States
Portland, Oregon, United States
Charleston, South Carolina, United States
Daytona Beach, Florida, United States
Kansas City, Kansas, United States
Boston, Massachusetts, United States
Santa Fe, New Mexico, United States
Cleveland, Ohio, United States
Providence, Rhode Island, United States
Spokane, Washington, United States
Corona, California, United States
Aurora, Colorado, United States
Colorado Springs, Colorado, United States
Chattanooga, Tennessee, United States
Montreal, Quebec, Canada
Tulsa, Oklahoma, United States
Vancouver, British Columbia, Canada
Toronto, Ontario, Canada
Iowa City, Iowa, United States
Edmonton, Alberta, Canada
Hamilton, Ontario, Canada
Detroit, Michigan, United States
Jupiter, Florida, United States
Lexington, Kentucky, United States
Ann Arbor, Michigan, United States
Lawrenceville, Georgia, United States
Waterford, Connecticut, United States
Beach Grove, Indiana, United States
Salina, Kansas, United States
Lawton, Oklahoma, United States
Sheboygan, Wisconsin, United States
Patients applied
Trial Officials
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials